Capturing the Complexity of the Human Gut
Our goal is to enable pharmaceutical companies to identify effective compounds earlier, before clinical trials; to reduce animal testing; and to make the drug development process faster, cheaper, and safer through New Approach Methodologies (NAMs).
RepliGut Systems: The next generation NAMs for human intestinal biology
The RepliGut® Planar model is a reproducible and scalable human intestine platform that is suitable for studying many aspects of drug disposition and pharmacology including toxicity, metabolism, drug absorption, and efficacy.
GI Toxicity
Screen compounds for drug-induced GI toxicity earlier in development
Intestinal Barrier Function
Characterize barrier integrity in response to challenges
Inflammatory Response
Evaluate pro- and anti- inflammatory effects of new modalities
Intestinal Drug Disposition
Broaden bioavailability insights compared to Caco-2 cells
The need for better human intestinal models
The current lack of user-friendly pre-clinical pharmacological testing models for the human intestine significantly hinders our ability to develop new therapies for intestinal disorders. Additionally, it presents a challenge in ensuring the safe passage of orally administered treatments for other conditions through the gut without unwanted side effects. These challenges are driving adoption of NAMs that better reflect human biology.
RepliGut® Systems
Altis Biosystems has pioneered the creation of RepliGut® Systems, a collection of in vitro models derived from stem cells and designed specifically for pre-clinical drug discovery. RepliGut® models are designed to replicate the complex structure of the human small intestine and colonic epithelium using a standard user friendly format.
RepliGut® models represent a scalable NAM platform for intestinal drug discovery and toxicology. RepliGut models deliver valuable data insights, rapid screening capabilities, and an unparalleled biobank of ethically sourced donor intestinal cells, paving the way for more effective compound screening, disease modeling, and microbiome research.
Advancing NAMs to Reduce Animal Testing
Derived from adult human donor stem cells, these innovative systems overcome the constraints of conventional cell lines and animal models, providing a highly accurate representation of human intestinal physiology.
Through the replication of native human biology, we are able to deliver a wealth of physiologically relevant preclinical insights, ultimately enhancing the performance of clinical trials and diminishing the necessity for animal testing.
Our Experience Is Your Advantage
See how our clients are using RepliGut Systems.
Poster Download
Altis R&D
A Sensitive and Specific Human Primary Stem Cell-Based In Vitro Assay for Predicting The Gastrointestinal Toxicity Risk of Therapeutic Agents
Poster Download
Janssen R&D
Human Small Intestine Monolayers For Assessing Drug-Induced Intestinal Liabilities In Vitro
Poster Download
Janssen R&D with UNC-Chapel Hill
Characterization of a novel human primary intestinal epithelial monolayer platform in response to a cytokine challenge
Poster Download
CN-Bio
A primary jejunum and primary hepatocyte multi-organ MPS: a promising tool for more predictive studies of human drug ADME and oral bioavailability
"The RepliGut kits have been extremely easy to use; just by following the provided instructions I have never had a problem getting the cells to perform as expected."
Elizabeth Jaensch, Fog Pharma
Ready to Go With Your Gut?
Contact us to learn more about RepliGut® Model Kits and Services.